Edwards Q2 Beats on TAVR, TMTT Strength but Premium Multiple Caps Upside

What happened

Edwards Lifesciences reported Q2 2026 sales of $1.74B, up 13.6%, with TAVR growing 11.3% to $1.26B and TMTT reaching $195.9M, driven by its portfolio of repair and replacement therapies. Adjusted EPS of $0.78 exceeded consensus, and recent clinical data at New York Valves reinforced its best-in-class positioning. This performance validates the company's execution on TAVR and TMTT growth, but the stock's premium multiple leaves limited room for error. Despite strong results, the FTC's blocked JenaValve deal and recurring quality issues remain overhangs. The base case of 6–8% TAVR growth and TMTT scaling appears on track, but the valuation already prices in continued success.

Implication

Investors should monitor if TAVR growth sustains above 10% and TMTT tracks toward $740-780M in 2026, but the risk/reward remains unattractive from current levels. A pullback below $75 with intact guidance would offer a better entry. The neutral 'WAIT' stance is reinforced.

Thesis delta

The strong Q2 results increase confidence in the base case but do not alter the neutral stance; the stock remains at the upper end of fair value. The earlier thesis flagged limited upside at ~$84; this beat may push price higher, but without a pullback, the margin of safety remains thin.